Datasets:
Inabia-AI
/
continued-pretraining

Dataset card Data Studio Files
xet
 Community
1
text
stringlengths
1
5.46k
ARTICLE 11 INDEMNITY .................................................................................................... 122
11.1 Indemnification of Calibr. ................................................................................ 122
11.2 Indemnification of AbbVie............................................................................... 122
11.3 Indemnification Procedures. ............................................................................. 123
11.4 Special, Indirect and Other Losses.................................................................... 126
11.5 Insurance ......................................................................................................... 126
ARTICLE 12 TERM AND TERMINATION .......................................................................... 127
12.1 Term and Expiration. ....................................................................................... 127
12.2 Termination ..................................................................................................... 127
12.3 Rights in Bankruptcy........................................................................................ 130
12.4 Consequences of Termination .......................................................................... 130
12.5 AbbVie Rights in Lieu of Termination ............................................................. 134
12.6 Remedies ......................................................................................................... 135
12.7 Accrued Rights; Surviving Obligations ............................................................ 135
ARTICLE 13 MISCELLANEOUS ......................................................................................... 136
13.1 Force Majeure. ................................................................................................. 136
13.2 Export Control. ................................................................................................ 137
13.3 Assignment ...................................................................................................... 137
13.4 Severability ...................................................................................................... 138
13.5 Dispute Resolution ........................................................................................... 138
13.6 Governing Law ................................................................................................ 139
13.7 Notices ............................................................................................................. 139
13.8 Entire Agreement; Amendments ...................................................................... 140
13.9 English Language............................................................................................. 140
13.10 Equitable Relief ............................................................................................... 140
13.11 Specific Performance ....................................................................................... 141
13.12 Waiver and Non-Exclusion of Remedies .......................................................... 141
13.13 No Benefit to Third Parties............................................................................... 141
13.14 Further Assurance. ........................................................................................... 141
13.15 Relationship of the Parties. ............................................................................... 142
13.16 HSR Act Compliance ....................................................................................... 142
13.17 References ....................................................................................................... 142
13.18 Construction..................................................................................................... 142
13.19 Amendment and Restatement ........................................................................... 143
13.20 Performance by Affiliates ................................................................................ 143
13.21 Counterparts..................................................................................................... 143
Schedules
Schedule 1.72 CD19 Autoimmune Subplan
Schedule 1.80 CD19 Plan
Schedule 1.94 Corporate Names
Schedule 1.119 Existing Patent Schedule
Schedule 1.121 Existing Targets
Schedule 1.129 Failed Target Criteria
Schedule 1.139 FTE Rates
Schedule 1.149 In-License Schedule
Schedule 1.225 PRLR Switch Plan
Schedule 1.273 Target Research Plan
Schedule 1.273(a) PRLR Interim Research Plan
Schedule 2.3.2-a mRNA Work Plan
Schedule 2.3.2-b In-Situ Work Plan
Schedule 2.6.3 Key Personnel
Schedule 7.6.4 Example Royalty Calculations
Schedule 9.1.2 Form of Employee Non-Disclosure Agreement
Schedule 9.5 Press Release
Schedule 10.2.1 Initial Disclosure Schedules
Schedule 10.2.1(o) Federally Funded Inventions
Schedule 10.2.2 A&R Disclosure Schedules
Schedule 10.2.2(o) Federally Funded Inventions
Schedule 10.2.3 Representations and Warranties as of the CD19 Option Bringdown Date
Schedule 10.2.4 Representations and Warranties as of the Existing Target ROFN Bringdown Date
Schedule 10.2.5 Representations and Warranties as of the Platform Option Bringdown Date
Schedule 10.3.3 Scripps License Agreement Amendment
Schedule 13.5 Arbitration
AMENDED AND RESTATED LICENSE AGREEMENT
This Amended and Restated License Agreement (this "Agreement") is made and entered into as of September 29, 2023 (the "A&R Effective Date") by and between The Scripps Research Institute, a California nonprofit public benefit corporation located at 10550 North Torrey Pines Road, La Jolla, California 92037, as successor ...
RECITALS
WHEREAS, Calibr is engaged in translational research and the discovery and development, in each case for the public benefit, of biological pharmaceutical product candidates for the prevention, diagnosis or treatment of diseases through the use of its proprietary sCAR-T Platform (as defined below);
WHEREAS, Calibr owns and controls certain intellectual property rights with respect to the sCAR-T Platform in the Territory (as defined below);
WHEREAS, Calibr and AbbVie entered into that certain License Agreement dated June 21, 2018 (such date the "Original Execution Date" and such agreement, the "Original License Agreement"); and
WHEREAS, the Parties wish to amend and restate the Original License Agreement to, among other things, extend the exclusivity period with respect to the sCAR-T Platform and provide for Calibr to perform additional Development (as defined below) activities with respect to certain programs of interest to AbbVie.
NOW, THEREFORE, in consideration of the premises and the mutual promises and conditions set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, do hereby agree as follows:
ARTICLE 1 DEFINITIONS
Unless otherwise specifically provided herein, the following terms shall have the following meanings:
1.1 "A&R Disclosure Schedules" has the meaning set forth in Section 10.2.2.
1.2 "A&R Effective Date" has the meaning set forth in the preamble hereto.
1.3 "AbbVie" has the meaning set forth in the preamble hereto.
1.4 "AbbVie Consideration Period" has the meaning set forth in Section 2.1.6(d).
1.5 "AbbVie Development Cost Report" has the meaning set forth in Section 3.3.4.
1.6 "AbbVie Development Costs" means, with respect to a Cost-Share Product, the FTE Costs and the Out-of-Pocket Costs incurred by or on behalf of AbbVie or any of its Affiliates, commencing on the date on which the relevant Cost-Sharing Option Period begins, in accordance with the Accounting Standards and this Agreemen...
1.7 "AbbVie Grantback IP" means, with respect to any Reversion Product, (a) any Program Product Inventions that are necessary or reasonably useful for the Exploitation of such Reversion Product and (b) any Program Product Patents that claim any Program Product Inventions described in the foregoing clause (a).
1.8 "AbbVie Indemnitees" has the meaning set forth in Section 11.2.
1.9 "AbbVie Independent Information" means any Information owned or otherwise controlled by AbbVie or its Affiliates that is generated independently of this Agreement and without use of Calibr IP.
1.10 "AbbVie IP" means AbbVie Know-How and AbbVie Patents.
1.11 "AbbVie Know-How" means any and all (a) Information Controlled by AbbVie or any of its Affiliates as of the Original Execution Date or at any time during the Term, other than any AbbVie Sole Inventions, Program Product Inventions or Joint Know-How, that is reasonably necessary or useful for the Development of a Re...
1.12 "AbbVie Materials" has the meaning set forth in Section 2.7.
1.13 "AbbVie Patents" means any and all (a) Patents Controlled by AbbVie or any of its Affiliates as of the Original Execution Date or at any time during the Term, other than any AbbVie Sole Patents, Program Product Patents or Joint Patents, that are reasonably necessary or useful for the Development of a Research Targ...
1.14 "AbbVie Platform Improvement IP" means any and all modifications, enhancements and improvements to the sCAR-T Platform (or any Calibr Component) conceived, discovered, developed or otherwise made by or on behalf of AbbVie or any of its Affiliates under this Agreement to the extent such modification, enhancement or...
1.15 "AbbVie Sensitive Information" has the meaning set forth in Section 9.6.1.
1.16 "AbbVie Sole Inventions" has the meaning set forth in Section 8.1.1.
1.17 "AbbVie Sole Patents" has the meaning set forth in Section 8.1.1.
1.18 "AbbVie Target" means any Research Target excluding any Research Target (a) for which, as of the Inclusion Date for such Research Target, Calibr or any of its Affiliates had performed any in vivo assay with respect to any biopharmaceutical product Directed to such Research Target for any of the indications for whi...
1.19 "AbbVie Target Information" means, with respect to an AbbVie Target, (a) the identity of such AbbVie Target, (b) the indications for which the Parties are conducting activities under the Target Research Plan for such AbbVie Target, (c) the sequences of such AbbVie Target and any potential post-translational modifi...
1.20 "Academic Collaborations" has the meaning set forth in Section 4.7.4.
1.21 "Academic Collaborator" means any Third Party that Calibr licenses, authorizes, appoints, or otherwise assists or enables in connection with an Academic Collaboration.
1.22 "Acceptance Date" means, with respect to a Reviewable Data Package, (a) if AbbVie does not request that such Reviewable Data Package be updated with any missing information or data pursuant to Section 2.10.4, the date AbbVie receives such Reviewable Data Package and (b) if AbbVie requests that such Reviewable Data...
1.23 "Accounting Standards" means, with respect to a Party or its Affiliates or its or their (sub)licensees, United States generally accepted accounting principles, consistently applied.
1.24 "Acquirer IP" has the meaning set forth in Section 13.3.2.
1.25 "Acquiring Entities" has the meaning set forth in Section 13.3.2.
1.26 "Acquisition Party" has the meaning set forth in Section 13.3.2.
1.27 "Acquisition Transaction" has the meaning set forth in Section 13.3.2.